CRISPR Therapeutics (CRSP) Misses Q1 EPS by 37c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $7.1 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Axis Capital Limited Upgrades Coforge Ltd (COFORGE:IN) to Buy (1)
• Cerebras Q1 EPS miss sends shares down 9% after-hours